1
|
Marongiu F, Cheri S, Laconi E. Clones of aging: When better fitness can be dangerous. Eur J Cell Biol 2023; 102:151340. [PMID: 37423036 DOI: 10.1016/j.ejcb.2023.151340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 05/29/2023] [Accepted: 07/05/2023] [Indexed: 07/11/2023] Open
Abstract
The biological and clinical significance of aberrant clonal expansions in aged tissues is being intensely discussed. Evidence is accruing that these clones often result from the normal dynamics of cell turnover in our tissues. The aged tissue microenvironment is prone to favour the emergence of specific clones with higher fitness partly because of an overall decline in cell intrinsic regenerative potential of surrounding counterparts. Thus, expanding clones in aged tissues need not to be mechanistically associated with the development of cancer, albeit this is a possibility. We suggest that growth pattern is a critical phenotypic attribute that impacts on the fate of such clonal proliferations. The acquisition of a better proliferative fitness, coupled with a defect in tissue pattern formation, could represent a dangerous mix setting the stage for their evolution towards neoplasia.
Collapse
Affiliation(s)
- Fabio Marongiu
- Department of Biomedical Sciences, University of Cagliari, Italy
| | - Samuele Cheri
- Department of Biomedical Sciences, University of Cagliari, Italy
| | - Ezio Laconi
- Department of Biomedical Sciences, University of Cagliari, Italy.
| |
Collapse
|
2
|
Dalle Carbonare L, Bertacco J, Gaglio SC, Minoia A, Cominacini M, Cheri S, Deiana M, Marchetto G, Bisognin A, Gandini A, Antoniazzi F, Perduca M, Mottes M, Valenti MT. Fisetin: An Integrated Approach to Identify a Strategy Promoting Osteogenesis. Front Pharmacol 2022; 13:890693. [PMID: 35652047 PMCID: PMC9149166 DOI: 10.3389/fphar.2022.890693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Accepted: 04/11/2022] [Indexed: 11/13/2022] Open
Abstract
Flavonoids may modulate the bone formation process. Among flavonoids, fisetin is known to counteract tumor growth, osteoarthritis, and rheumatoid arthritis. In addition, fisetin prevents inflammation-induced bone loss. In order to evaluate its favorable use in osteogenesis, we assayed fisetin supplementation in both in vitro and in vivo models and gathered information on nanoparticle-mediated delivery of fisetin in vitro and in a microfluidic system. Real-time RT-PCR, Western blotting, and nanoparticle synthesis were performed to evaluate the effects of fisetin in vitro, in the zebrafish model, and in ex vivo samples. Our results demonstrated that fisetin at 2.5 µM concentration promotes bone formation in vitro and mineralization in the zebrafish model. In addition, we found that fisetin stimulates osteoblast maturation in cell cultures obtained from cleidocranial dysplasia patients. Remarkably, PLGA nanoparticles increased fisetin stability and, consequently, its stimulating effects on RUNX2 and its downstream gene SP7 expression. Therefore, our findings demonstrated the positive effects of fisetin on osteogenesis and suggest that patients affected by skeletal diseases, both of genetic and metabolic origins, may actually benefit from fisetin supplementation.
Collapse
Affiliation(s)
| | - Jessica Bertacco
- Department of Medicine, University of Verona, Verona, Italy.,Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| | | | - Arianna Minoia
- Department of Medicine, University of Verona, Verona, Italy
| | | | - Samuele Cheri
- Department of Medicine, University of Verona, Verona, Italy
| | - Michela Deiana
- Department of Medicine, University of Verona, Verona, Italy
| | | | - Anna Bisognin
- Biocrystallography Lab, Department of Biotechnology, University of Verona, Verona, Italy
| | - Alberto Gandini
- Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy
| | - Franco Antoniazzi
- Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy
| | - Massimiliano Perduca
- Biocrystallography Lab, Department of Biotechnology, University of Verona, Verona, Italy
| | - Monica Mottes
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - Maria Teresa Valenti
- Department of Medicine, University of Verona, Verona, Italy.,Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
| |
Collapse
|
3
|
Abstract
Complex multicellular organisms require quantitative and qualitative assessments on each of their constitutive cell types to ensure coordinated and cooperative behavior towards overall functional proficiency. Cell competition represents one of the operating arms of such quality control mechanisms and relies on fitness comparison among individual cells. However, what is exactly included in the fitness equation for each cell type is still uncertain. Evidence will be discussed to suggest that the ability of the cell to integrate and collaborate within the organismal community represents an integral part of the best fitness phenotype. Thus, under normal conditions, cell competition will select against the emergence of altered cells with disruptive behavior towards tissue integrity and/or tissue pattern formation. On the other hand, the winner phenotype prevailing as a result of cell competition does not entail, by itself, any degree of growth autonomy. While cell competition per se should not be considered as a biological driving force towards the emergence of the neoplastic phenotype, it is possible that the molecular machinery involved in the winner/loser interaction could be hijacked by evolving cancer cell populations.
Collapse
Affiliation(s)
- Fabio Marongiu
- Department of Biomedical Sciences, University of Cagliari, Italy
| | - Samuele Cheri
- Department of Biomedical Sciences, University of Cagliari, Italy
| | - Ezio Laconi
- Department of Biomedical Sciences, University of Cagliari, Italy.
| |
Collapse
|
4
|
Dalle Carbonare L, Bertacco J, Marchetto G, Cheri S, Deiana M, Minoia A, Tiso N, Mottes M, Valenti MT. Methylsulfonylmethane enhances MSC chondrogenic commitment and promotes pre-osteoblasts formation. Stem Cell Res Ther 2021; 12:326. [PMID: 34090529 PMCID: PMC8180127 DOI: 10.1186/s13287-021-02396-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Accepted: 05/18/2021] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Methylsulfonylmethane (MSM) is a nutraceutical compound which has been indicated to counteract osteoarthritis, a cartilage degenerative disorder. In addition, MSM has also been shown to increase osteoblast differentiation. So far, few studies have investigated MSM role in the differentiation of mesenchymal stem cells (MSCs), and no study has been performed to evaluate its overall effects on both osteogenic and chondrogenic differentiation. These two mutually regulated processes share the same progenitor cells. METHODS Therefore, with the aim to evaluate the effects of MSM on chondrogenesis and osteogenesis, we analyzed the expression of SOX9, RUNX2, and SP7 transcription factors in vitro (mesenchymal stem cells and chondrocytes cell lines) and in vivo (zebrafish model). Real-time PCR as well Western blotting, immunofluorescence, and specific in vitro and in vivo staining have been performed. Student's paired t test was used to compare the variation between the groups. RESULTS Our data demonstrated that MSM modulates the expression of differentiation-related genes both in vitro and in vivo. The increased SOX9 expression suggests that MSM promotes chondrogenesis in treated samples. In addition, RUNX2 expression was not particularly affected by MSM while SP7 expression increased in all MSM samples/model analyzed. As SP7 is required for the final commitment of progenitors to preosteoblasts, our data suggest a role of MSM in promoting preosteoblast formation. In addition, we observed a reduced expression of the osteoclast-surface receptor RANK in larvae and in scales as well as a reduced pERK/ERK ratio in fin and scale of MSM treated zebrafish. CONCLUSIONS In conclusion, our study provides new insights into MSM mode of action and suggests that MSM is a useful tool to counteract skeletal degenerative diseases by targeting MSC commitment and differentiation.
Collapse
Affiliation(s)
- Luca Dalle Carbonare
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Jessica Bertacco
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie, 10, 37100, Verona, Italy
| | - Giulia Marchetto
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Samuele Cheri
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Michela Deiana
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Arianna Minoia
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Natascia Tiso
- Department of Biology, University of Padova, I-35131, Padova, Italy
| | - Monica Mottes
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Strada Le Grazie, 10, 37100, Verona, Italy
| | - Maria Teresa Valenti
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
| |
Collapse
|
5
|
Valenti MT, Mattè A, Federti E, Puder M, Anez-Bustillos L, Deiana M, Cheri S, Minoia A, Brugnara C, Di Paolo ML, Dalle Carbonare L, De Franceschi L. Dietary ω-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants (Basel) 2021; 10:antiox10050799. [PMID: 34070133 PMCID: PMC8158389 DOI: 10.3390/antiox10050799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 05/01/2021] [Accepted: 05/12/2021] [Indexed: 12/28/2022] Open
Abstract
Sickle cell disease (SCD) is a genetic disorder of hemoglobin, leading to chronic hemolytic anemia and multiple organ damage. Among chronic organ complications, sickle cell bone disease (SBD) has a very high prevalence, resulting in long-term disability, chronic pain and fractures. Here, we evaluated the effects of ω-3 (fish oil-based, FD)-enriched diet vs. ω-6 (soybean oil-based, SD)- supplementation on murine SBD. We exposed SCD mice to recurrent hypoxia/reoxygenation (rec H/R), a consolidated model for SBD. In rec H/R SS mice, FD improves osteoblastogenesis/osteogenic activity by downregulating osteoclast activity via miR205 down-modulation and reduces both systemic and local inflammation. We also evaluated adipogenesis in both AA and SS mice fed with either SD or FD and exposed to rec H/R. FD reduced and reprogramed adipogenesis from white to brown adipocyte tissue (BAT) in bone compartments. This was supported by increased expression of uncoupling protein 1(UCP1), a BAT marker, and up-regulation of miR455, which promotes browning of white adipose tissue. Our findings provide new insights on the mechanism of action of ω-3 fatty acid supplementation on the pathogenesis of SBD and strengthen the rationale for ω-3 fatty acid dietary supplementation in SCD as a complementary therapeutic intervention.
Collapse
Affiliation(s)
- Maria Teresa Valenti
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Alessandro Mattè
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Enrica Federti
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Mark Puder
- Department of Surgery and The Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; (M.P.); (L.A.-B.)
| | - Lorenzo Anez-Bustillos
- Department of Surgery and The Vascular Biology Program, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; (M.P.); (L.A.-B.)
| | - Michela Deiana
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Samuele Cheri
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Arianna Minoia
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| | - Carlo Brugnara
- Departments of Pathology and Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA;
| | | | - Luca Dalle Carbonare
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
- Correspondence: ; Tel.: +39-045-812-4401
| | - Lucia De Franceschi
- Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, 37128 Verona, Italy; (M.T.V.); (A.M.); (E.F.); (M.D.); (S.C.); (A.M.); (L.D.F.)
| |
Collapse
|
6
|
Deiana M, Malerba G, Dalle Carbonare L, Cheri S, Patuzzo C, Tsenov G, Moron Dalla Tor L, Mori A, Saviola G, Zipeto D, Schena F, Mottes M, Valenti MT. Physical Activity Prevents Cartilage Degradation: A Metabolomics Study Pinpoints the Involvement of Vitamin B6. Cells 2019; 8:cells8111374. [PMID: 31683926 PMCID: PMC6912200 DOI: 10.3390/cells8111374] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 10/23/2019] [Accepted: 10/31/2019] [Indexed: 12/29/2022] Open
Abstract
Osteoarthritis (OA) is predominantly characterized by the progressive degradation of articular cartilage, the connective tissue produced by chondrocytes, due to an imbalance between anabolic and catabolic processes. In addition, physical activity (PA) is recognized as an important tool for counteracting OA. To evaluate PA effects on the chondrocyte lineage, we analyzed the expression of SOX9, COL2A1, and COMP in circulating progenitor cells following a half marathon (HM) performance. Therefore, we studied in-depth the involvement of metabolites affecting chondrocyte lineage, and we compared the metabolomic profile associated with PA by analyzing runners’ sera before and after HM performance. Interestingly, this study highlighted that metabolites involved in vitamin B6 salvage, such as pyridoxal 5′-phosphate and pyridoxamine 5′-phosphate, were highly modulated. To evaluate the effects of vitamin B6 in cartilage cells, we treated differentiated mesenchymal stem cells and the SW1353 chondrosarcoma cell line with vitamin B6 in the presence of IL1β, the inflammatory cytokine involved in OA. Our study describes, for the first time, the modulation of the vitamin B6 salvage pathway following PA and suggests a protective role of PA in OA through modulation of this pathway.
Collapse
Affiliation(s)
- Michela Deiana
- Department of Medicine, Internal Medicine, Section D, University of Verona, I-37134 Verona, Italy.
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Giovanni Malerba
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Luca Dalle Carbonare
- Department of Medicine, Internal Medicine, Section D, University of Verona, I-37134 Verona, Italy.
| | - Samuele Cheri
- Department of Medicine, Internal Medicine, Section D, University of Verona, I-37134 Verona, Italy.
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Cristina Patuzzo
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Grygoriy Tsenov
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Lucas Moron Dalla Tor
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Antonio Mori
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Gianantonio Saviola
- Istituti Clinici Scientifici Maugeri IRCCS, Rheumatology and Rehabilitation Uniti of the Institute of Castel Goffredo, I-46042 Mantua, Italy.
| | - Donato Zipeto
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Federico Schena
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Monica Mottes
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, I-37134 Verona, Italy.
| | - Maria Teresa Valenti
- Department of Medicine, Internal Medicine, Section D, University of Verona, I-37134 Verona, Italy.
| |
Collapse
|
7
|
Valenti MT, Mottes M, Cheri S, Deiana M, Micheletti V, Cosaro E, Davì MV, Francia G, Dalle Carbonare L. Runx2 overexpression compromises bone quality in acromegalic patients. Endocr Relat Cancer 2018; 25:269-277. [PMID: 29295822 DOI: 10.1530/erc-17-0523] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 01/02/2018] [Indexed: 12/12/2022]
Abstract
Acromegalic patients, characterized by excessive secretion of GH and IGF-1, show a high fracture risk but bone mineral density is a poor predictor for bone fractures in these patients. The effects of an excess of GH/IGF1 on skeleton as well as on osteogenic progenitors, i.e. mesenchymal stem cells, have not been investigated in these patients. We aimed to elucidate the skeletal conditions of acromegalic patients by means of bone microarchitecture analysis and evaluation of MSCs osteogenic commitment. In particular, we performed histomorphometric analyses, and we quantified the expression levels of the osteogenic transcription factor RUNX2 in circulating MSCs. Our results showed an abnormal microarchitecture and demonstrated that bone impairment in acromegalic patients is associated with the upregulation of RUNX2 expression. Furthermore, osteoblastic activity was significantly reduced in patients under pharmacological treatment, compared to untreated patients. In conclusion, this study demonstrates the key role of RUNX2 gene overexpression in causing bone impairment in acromegalic patients. It also suggests a therapeutic approach for the improvement of bone quality, focused on the osteoblastic lineage rather than the inhibition of osteoclastic activity.
Collapse
Affiliation(s)
- Maria Teresa Valenti
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| | - Monica Mottes
- Department of NeurosciencesBiomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - Samuele Cheri
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
- Department of NeurosciencesBiomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - Michela Deiana
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
- Department of NeurosciencesBiomedicine and Movement Sciences, University of Verona, Verona, Italy
| | - Valentina Micheletti
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| | - Elisa Cosaro
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| | - Maria Vittoria Davì
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| | - Giuseppe Francia
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| | - Luca Dalle Carbonare
- Department of MedicineInternal Medicine, Section D, University of Verona, Verona, Italy
| |
Collapse
|
8
|
Cecconi D, Carbonare LD, Mori A, Cheri S, Deiana M, Brandi J, Degaetano V, Masiero V, Innamorati G, Mottes M, Malerba G, Valenti MT. An integrated approach identifies new oncotargets in melanoma. Oncotarget 2017; 9:11489-11502. [PMID: 29545914 PMCID: PMC5837771 DOI: 10.18632/oncotarget.23727] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 10/16/2017] [Indexed: 12/31/2022] Open
Abstract
Melanoma is an aggressive skin cancer; an early detection of the primary tumor may improve its prognosis. Despite many genes have been shown to be involved in melanoma, the full framework of melanoma transformation has not been completely explored. The characterization of pathways involved in tumor restraint in in vitro models may help to identify oncotarget genes. We therefore aimed to probe novel oncotargets through an integrated approach involving proteomic, gene expression and bioinformatic analysis We investigated molecular modulations in melanoma cells treated with ascorbic acid, which is known to inhibit cancer growth at high concentrations. For this purpose a proteomic approach was applied. A deeper insight into ascorbic acid anticancer activity was achieved; the discovery of deregulated processes suggested further biomarkers. In addition, we evaluated the expression of identified genes as well as the migration ability in several melanoma cell lines. Data obtained by a multidisciplinary approach demonstrated the involvement of Enolase 1 (ENO1), Parkinsonism-associated deglycase (PARK7), Prostaglansin E synthase 3 (PTGES3), Nucleophosmin (NPM1), Stathmin 1 (STMN1) genes in cell transformation and identified Single stranded DNA binding protein 1 (SSBP1) as a possible onco-suppressor in melanoma cancer.
Collapse
Affiliation(s)
- Daniela Cecconi
- Department of Biotechnology, Mass Spectrometry and Proteomics Lab, University of Verona, 37134 Verona, Italy
| | - Luca Dalle Carbonare
- Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy
| | - Antonio Mori
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
| | - Samuele Cheri
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
| | - Michela Deiana
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
| | - Jessica Brandi
- Department of Biotechnology, Mass Spectrometry and Proteomics Lab, University of Verona, 37134 Verona, Italy
| | - Vincenzo Degaetano
- Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy
| | - Valentina Masiero
- Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy
| | - Giulio Innamorati
- Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy
| | - Monica Mottes
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
| | - Giovanni Malerba
- Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
| | - Maria Teresa Valenti
- Department of Medicine, Internal Medicine, Section D, University of Verona, 37134 Verona, Italy
| |
Collapse
|
9
|
Valenti MT, Mottes M, Biotti A, Perduca M, Pisani A, Bovi M, Deiana M, Cheri S, Dalle Carbonare L. Clodronate as a Therapeutic Strategy against Osteoarthritis. Int J Mol Sci 2017; 18:ijms18122696. [PMID: 29236045 PMCID: PMC5751297 DOI: 10.3390/ijms18122696] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 12/04/2017] [Accepted: 12/08/2017] [Indexed: 01/31/2023] Open
Abstract
Osteoarthritis (OA), the most prevalent musculoskeletal pathology, is mainly characterized by the progressive degradation of articular cartilage due to an imbalance between anabolic and catabolic processes. Consequently, OA has been associated with defects in the chondrocitic differentiation of progenitor stem cells (PSCs). In addition, SOX9 is the transcription factor responsible for PSCs chondrogenic commitment. To evaluate the effects of the non-amino bisphosphonate clodronate in OA patients we investigated SOX9 gene expression in circulating progenitor cells (CPCs) and in an in vitro OA model. We evaluated pain intensity, mental and physical performance in OA patients, as well as serum biomarkers related to bone metabolism. In addition, in order to improve therapeutic strategies, we assayed nanoparticle-embedded clodronate (NPs-clo) in an in vitro model of chondrogenic differentiation. Our data showed upregulation of SOX9 gene expression upon treatment, suggesting an increase in chondrocytic commitment. Clodronate also reduced osteoarticular pain and improved mental and physical performance in patients. Furthermore, NPs-clo stimulated SOX9 expression more efficaciously than clodronate alone. Clodronate may therefore be considered a good therapeutic tool against OA; its formulation in nanoparticles may represent a promising challenge to counteract cartilage degeneration.
Collapse
Affiliation(s)
- Maria Teresa Valenti
- Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy.
| | - Monica Mottes
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
| | - Alessandro Biotti
- Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy.
| | - Massimiliano Perduca
- Biocrystallography Lab, Department of Biotechnology, University of Verona, 37134 Verona, Italy.
| | - Arianna Pisani
- Biocrystallography Lab, Department of Biotechnology, University of Verona, 37134 Verona, Italy.
| | - Michele Bovi
- Biocrystallography Lab, Department of Biotechnology, University of Verona, 37134 Verona, Italy.
| | - Michela Deiana
- Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy.
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
| | - Samuele Cheri
- Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy.
- Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
| | - Luca Dalle Carbonare
- Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy.
| |
Collapse
|
10
|
Dalle Carbonare L, Manfredi M, Caviglia G, Conte E, Robotti E, Marengo E, Cheri S, Zamboni F, Gabbiani D, Deiana M, Cecconi D, Schena F, Mottes M, Valenti MT. Can half-marathon affect overall health? The yin-yang of sport. J Proteomics 2017; 170:80-87. [PMID: 28887210 DOI: 10.1016/j.jprot.2017.09.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 08/18/2017] [Accepted: 09/05/2017] [Indexed: 12/16/2022]
Abstract
Physical activity improves overall health and counteracts metabolic pathologies. Adipose tissue and bone are important key targets of exercise; the prevalence of diseases associated with suboptimal physical activity levels has increased in recent times as a result of lifestyle changes. Mesenchymal stem cells (MSCs) differentiation in either osteogenic or adipogenic lineage is regulated by many factors. Particularly, the expression of master genes such as RUNX2 and PPARγ2 is essential for MSC commitment to osteogenic or adipogenic differentiation, respectively. Besides various positive effects on health, some authors have reported stressful outcomes as a consequence of endurance in physical activity. We looked for further clues about MSCs differentiation and serum proteins modulation studying the effects of half marathon in runners by means of gene expression analyses and a proteomic approach. Our results demonstrated an increase in osteogenic commitment and a reduction in adipogenic commitment of MSCs. In addition, for the first time we have analyzed the proteomic profile changes in runners after half-marathon activity in order to survey the related systemic adjustments. The shotgun proteomic approach, performed through the immuno-depletion of the 14 most abundant serum proteins, allowed the identification of 23 modulated proteins after the half marathon. Interestingly, proteomic data showed the activation of both inflammatory response and detoxification process. Moreover, the involvement of pathways associated to immune response, lipid transport and coagulation, was elicited. Notably, positive and negative effects may be strictly linked. Data are available via ProteomeXchange with identifier PXD006704. SIGNIFICANCE We describe gene expression and proteomic studies aiming to an in-depth understanding of half-marathon effects on bone and adipogenic differentiation as well as biological phenomena involved in sport activity. We believe that this novel approach suggests the physical effects on overall health and show the different pathways involved during half marathon. Contents of the paper have not been published or submitted for publication elsewhere. The authors declare no conflict of interest.
Collapse
Affiliation(s)
- Luca Dalle Carbonare
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy
| | - Marcello Manfredi
- Department of Sciences and Technological Innovation, University of Piemonte Orientale, Italy; ISALIT, Spin-off of DISIT, University of Piemonte Orientale, Italy
| | - Giuseppe Caviglia
- Department of Sciences and Technological Innovation, University of Piemonte Orientale, Italy
| | - Eleonora Conte
- ISALIT, Spin-off of DISIT, University of Piemonte Orientale, Italy
| | - Elisa Robotti
- Department of Sciences and Technological Innovation, University of Piemonte Orientale, Italy
| | - Emilio Marengo
- Department of Sciences and Technological Innovation, University of Piemonte Orientale, Italy
| | - Samuele Cheri
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy; Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
| | - Francesco Zamboni
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy
| | - Daniele Gabbiani
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy
| | - Michela Deiana
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy; Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
| | - Daniela Cecconi
- Department of Biotechnology, Mass Spectrometry & Proteomics Lab, University of Verona, Italy
| | - Federico Schena
- Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
| | - Monica Mottes
- Dep. of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
| | - Maria Teresa Valenti
- Department of Medicine, Internal Medicine, Section D, University of Verona, Italy.
| |
Collapse
|
11
|
Perduca M, Carbonare LD, Bovi M, Innamorati G, Cheri S, Cavallini C, Scupoli MT, Mori A, Valenti MT. Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β-trefoil. Oncol Rep 2017; 37:2209-2214. [DOI: 10.3892/or.2017.5493] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Accepted: 02/09/2017] [Indexed: 11/06/2022] Open
|
12
|
Valenti MT, Serafini P, Innamorati G, Gili A, Cheri S, Bassi C, Dalle Carbonare L. Runx2 expression: A mesenchymal stem marker for cancer. Oncol Lett 2016; 12:4167-4172. [PMID: 27895787 DOI: 10.3892/ol.2016.5182] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 08/09/2016] [Indexed: 12/12/2022] Open
Abstract
The transcription factor runt-related transcription factor 2 (Runx2) is a master gene implicated in the osteogenic differentiation of mesenchymal stem cells, and thus serves a determinant function in bone remodelling and skeletal integrity. Various signalling pathways regulate Runx2 abundance, which requires a number of molecules to finely modulate its expression. Furthermore, this gene may be ectopically-expressed in cancer cells. Recent studies have reported the involvement of Runx2 in cell proliferation, epithelial-mesenchymal transition, apoptosis and metastatic processes, suggesting it may represent a useful therapeutic target in cancer treatment. However, studies evaluating this gene as a cancer marker are lacking. In the present study, Runx2 expression was analysed in 11 different cancer cell lines not derived from bone tumour. In addition, the presence of Runx2-related cell-free RNA was examined in the peripheral blood of 41 patients affected by different forms of tumours. The results demonstrated high expression levels of Runx2 in the cancer cell lines and identified the presence of Runx2-related cell-free RNA in the peripheral blood of patients with cancer. As compared with normal individuals, the expression level was increased by 14.2-fold in patients with bone metastases and by 4.01-fold in patients without metastases. The results of the present study therefore opens up the possibility to exploit Runx2 expression as a cancer biomarker allowing the use of minimally invasive approaches for diagnosis and follow-up.
Collapse
Affiliation(s)
- Maria Teresa Valenti
- Department of Medicine, Section of Internal Medicine D, University of Verona, I-37134 Verona, Italy; University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy
| | - Paola Serafini
- Department of Medicine, Section of Internal Medicine D, University of Verona, I-37134 Verona, Italy; University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy
| | - Giulio Innamorati
- University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy; Department of Surgery, Section of General Surgery B, University of Verona, I-37134 Verona, Italy
| | - Anna Gili
- University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy
| | - Samuele Cheri
- University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy
| | - Claudio Bassi
- Department of Surgery, Section of General Surgery B, University of Verona, I-37134 Verona, Italy
| | - Luca Dalle Carbonare
- Department of Medicine, Section of Internal Medicine D, University of Verona, I-37134 Verona, Italy; University Laboratory of Medical Research, University of Verona, I-37134 Verona, Italy
| |
Collapse
|